David O'Malley, MD

David O'Malley, MD, discusses antitumor activity with veliparib in combination with chemotherapy in patients with high grade serous ovarian cancer.

David O'Malley, MD, discusses the increased benefit of rucaparib maintenance in patients with ovarian cancer who express RAD51C/D mutations.

David O’Malley, MD, discusses the rationale to evaluate the clinical benefit of rucaparib maintenance treatment following disease progression in a subgroup of patients with ovarian cancer whose disease is associated with a mutation in a non-BRCA homologous recombination gene in the phase III ARIEL3 trial in ovarian cancer.

David O’Malley, MD, discusses the current state of immunotherapy in ovarian cancer.

David O’Malley, MD, discusses the state of immunotherapy in ovarian cancer.

David O’Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, and director, Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center–The James, discusses the optimal use of PARP inhibitors as frontline maintenance therapy in patients with advanced ovarian cancer.

David O’Malley, MD, discusses remaining questions in the ovarian cancer field.

David O’Malley, MD, discusses ongoing clinical trials evaluating immunotherapy in patients with advanced ovarian cancer.

David O’Malley, MD, discusses the toxicities associated with PARP inhibitors in ovarian cancer.

David O'Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center, discusses folate-receptor alpha as a biomarker in ovarian cancer.

David O’Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center, discusses the safety and efficacy results of the FORWARD II phase Ib study in patients with ovarian cancer.

David O'Malley, MD, gynecologic oncologist and an assistant professor in the Department of Obstetrics and Gynecology at The Ohio State University Wexner Medical Center, The Ohio State University Comprehensive Cancer Center, discusses the FDA approval of rucaparib (Rubraca)

David O'Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses combinations with PARP inhibitors in ovarian cancer.

David O'Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the tolerability of PARP inhibitors for patients with ovarian cancer.

David O'Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the current role for PARP inhibitors for patients with ovarian cancer.